-

Stephanie Reisinger to Lead Flatiron Health’s Real-World Evidence Business

Former Veradigm Executive Brings Extensive Experience in EHR-Derived Real-World Data

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced the appointment of Stephanie Reisinger as Senior Vice President and General Manager, Real-World Evidence (RWE), driving long-term strategy and growth for Flatiron’s RWE business unit.

“Stephanie brings a unique mix of expertise across electronic health records, real-world evidence, and analytics – the pillars of Flatiron’s work to learn from the experiences of every cancer patient,” said Carolyn Starrett, Flatiron CEO. “I’ve been deeply impressed by her perspective, accomplishments, and vision. Her leadership will help take our well-established products and evidence platform to the next level.”

Flatiron has led the field in the creation and use of RWE for oncology research and development (R&D). Today - together with a highly engaged care network of community sites, academic medical centers and health systems along with its life sciences and regulatory partners - Flatiron continues to drive and shape the future of oncology evidence generation.

Flatiron recognizes that to meaningfully accelerate R&D and access, to make research more inclusive and healthcare more sustainable, fundamental changes must be made in the way required data is collected, combined and analyzed. Through integrated evidence, knowledge can be generated in ways that go beyond today's methods – increasingly incorporating additional data modalities like genomics, claims and imaging; extending the stories told by clinical trial data with real-world data (RWD). Supported by Reisinger’s leadership, Flatiron will accelerate this vision to enable integrated evidence to power smarter care for every patient.

Prior to Flatiron, Reisinger served as the General Manager of Life Sciences Data and Analytics at Veradigm, an analytics subsidiary of Allscripts. She scaled the Life Sciences and RWE businesses, bridging the gap between Allscripts’ payer and provider data and life sciences partners, and oversaw operations and go-to-market strategy for this business unit. She has also held senior leadership positions in a variety of healthcare data and analytics organizations, including Evalytica, Evidera, United BioSource Corporation, ProSanos and GeneFormatics. Reisinger earned her bachelor’s degree at Widener University and is a candidate for her master’s in business administration at the Smeal College of Business at Penn State University.

“I am honored to join Flatiron, a global leader in transforming patients’ real-life experiences into knowledge to help accelerate improvements in cancer care and treatments,” said Reisinger. “I look forward to working closely with the organization's talented and mission-driven colleagues, as we continue to grow, lead and innovate. Flatiron has been at the forefront of developing real-world data for cancer research and I am delighted at the opportunity to be able to contribute to their mission and lead this next chapter of innovation alongside our partners.”

About Flatiron Health
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

Contacts

Flatiron Health

Details
Headquarters: New York, NY
CEO: Carolyn Starrett
Employees: 2,500
Organization: PRI

Release Summary
Flatiron Health Appointment
Release Versions

Contacts

More News From Flatiron Health

Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical Questions

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Genitourinary Cancers Symposium happening from February 26-28, 2026, in San Francisco, California. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 6 research acceptances spanning genitourinary cancers. A cornerstone of Flatiron’s presence at ASCO GU 2026 is the global prostate cancer and bladder cancer Panoramic datasets, which draw from o...

Flatiron Launches First-of-Its-Kind AI-Powered Global Prostate Cancer Datasets

NEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced their first Panoramic datasets in the UK and Germany for patients with prostate cancer. Globally, prostate cancer affects nearly 1.5 million patients annually and has a rapidly evolving treatment landscape, yet real-world evidence remains limited and infeasible to study across international borders. Flatiron is the first and on...

Flatiron Health Names New Chief Business, Technology, and Product Leaders

NEW YORK--(BUSINESS WIRE)--Flatiron Health is pleased to announce three significant appointments to its Executive Team, reflecting the critical, enterprise-level responsibilities these leaders have assumed and the company’s evolving direction. Michael Bierl will serve as Chief Business Officer, Allison Candido will serve as Chief Technology Officer, and Kate Estep will serve as Chief Product Officer. With decades of combined experience, Bierl, Candido, and Estep bring the leadership and experti...
Back to Newsroom